Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial

Heerajnarain Bulluck; Georg M. Fröhlich; Jennifer M. Nicholas; Shah Mohdnazri; Reto Gamma; John Davies; Alex Sirker; Anthony Mathur; Daniel Blackman; Pankaj Garg; James C. Moon; John P. Greenwood; Derek J. Hausenloy

doi:10.1016/j.ahj.2019.02.005

Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial

Heerajnarain Bulluck, Georg M. Fröhlich, Jennifer M. Nicholas, Shah Mohdnazri, Reto Gamma, John Davies, Alex Sirker, Anthony Mathur, Daniel Blackman, Pankaj Garg, James C. Moon, John P. Greenwood, Derek J. Hausenloy

Research output: Contribution to journal › Article › peer-review

19 Citations (Scopus)

10 Downloads (Pure)

Abstract

Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PPCI) accrues additional benefit of reducing myocardial infarct size and preventing adverse LV remodeling is not known. We aimed to investigate whether MRA therapy initiated prior to reperfusion reduces myocardial infarct (MI) size and prevents adverse LV remodeling in STEMI patients.

Original language	English
Pages (from-to)	60-67
Number of pages	8
Journal	American Heart Journal
Volume	211
Early online date	20 Feb 2019
DOIs	https://doi.org/10.1016/j.ahj.2019.02.005
Publication status	Published - 1 May 2019

Access to Document

10.1016/j.ahj.2019.02.005Licence: CC BY

Published_VersionFinal published version, 546 KBLicence: CC BY

https://linkinghub.elsevier.com/retrieve/pii/S0002870319300262Licence: CC BY

Cite this

Bulluck, H., Fröhlich, G. M., Nicholas, J. M., Mohdnazri, S., Gamma, R., Davies, J., Sirker, A., Mathur, A., Blackman, D., Garg, P., Moon, J. C., Greenwood, J. P., & Hausenloy, D. J. (2019). Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial. American Heart Journal, 211, 60-67. https://doi.org/10.1016/j.ahj.2019.02.005

Bulluck, Heerajnarain ; Fröhlich, Georg M. ; Nicholas, Jennifer M. ; Mohdnazri, Shah ; Gamma, Reto ; Davies, John ; Sirker, Alex ; Mathur, Anthony ; Blackman, Daniel ; Garg, Pankaj ; Moon, James C. ; Greenwood, John P. ; Hausenloy, Derek J. / Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial. In: American Heart Journal. 2019 ; Vol. 211. pp. 60-67.

@article{6571dde282754465aa81f795220b1fb9,

title = "Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial",

abstract = "Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PPCI) accrues additional benefit of reducing myocardial infarct size and preventing adverse LV remodeling is not known. We aimed to investigate whether MRA therapy initiated prior to reperfusion reduces myocardial infarct (MI) size and prevents adverse LV remodeling in STEMI patients.",

author = "Heerajnarain Bulluck and Fr{\"o}hlich, {Georg M.} and Nicholas, {Jennifer M.} and Shah Mohdnazri and Reto Gamma and John Davies and Alex Sirker and Anthony Mathur and Daniel Blackman and Pankaj Garg and Moon, {James C.} and Greenwood, {John P.} and Hausenloy, {Derek J.}",

year = "2019",

month = may,

day = "1",

doi = "10.1016/j.ahj.2019.02.005",

language = "English",

volume = "211",

pages = "60--67",

journal = "American Heart Journal",

issn = "0002-8703",

publisher = "Mosby Inc.",

}

Bulluck, H, Fröhlich, GM, Nicholas, JM, Mohdnazri, S, Gamma, R, Davies, J, Sirker, A, Mathur, A, Blackman, D, Garg, P, Moon, JC, Greenwood, JP & Hausenloy, DJ 2019, 'Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial', American Heart Journal, vol. 211, pp. 60-67. https://doi.org/10.1016/j.ahj.2019.02.005

Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial. / Bulluck, Heerajnarain; Fröhlich, Georg M.; Nicholas, Jennifer M.; Mohdnazri, Shah; Gamma, Reto; Davies, John; Sirker, Alex; Mathur, Anthony; Blackman, Daniel; Garg, Pankaj; Moon, James C.; Greenwood, John P.; Hausenloy, Derek J.

In: American Heart Journal, Vol. 211, 01.05.2019, p. 60-67.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial

AU - Bulluck, Heerajnarain

AU - Fröhlich, Georg M.

AU - Nicholas, Jennifer M.

AU - Mohdnazri, Shah

AU - Gamma, Reto

AU - Davies, John

AU - Sirker, Alex

AU - Mathur, Anthony

AU - Blackman, Daniel

AU - Garg, Pankaj

AU - Moon, James C.

AU - Greenwood, John P.

AU - Hausenloy, Derek J.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PPCI) accrues additional benefit of reducing myocardial infarct size and preventing adverse LV remodeling is not known. We aimed to investigate whether MRA therapy initiated prior to reperfusion reduces myocardial infarct (MI) size and prevents adverse LV remodeling in STEMI patients.

AB - Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PPCI) accrues additional benefit of reducing myocardial infarct size and preventing adverse LV remodeling is not known. We aimed to investigate whether MRA therapy initiated prior to reperfusion reduces myocardial infarct (MI) size and prevents adverse LV remodeling in STEMI patients.

U2 - 10.1016/j.ahj.2019.02.005

DO - 10.1016/j.ahj.2019.02.005

M3 - Article

VL - 211

SP - 60

EP - 67

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -